SCHEMBL4429045

SCHEMBL4429045

CN(C)CCn1c(=O)n(S(=O)(=O)c2cc(Cl)sc2Cl)c2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.40
CNR2 P34972 1/20 0.38
PTAFR P25105 1/20 0.37
HTR6 P50406 7/20 0.37
POLB P06746 2/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
CDK1 P06493 2/20 0.35
CCNB1 P14635 2/20 0.35
CCNA2 P20248 2/20 0.35
CCND1 P24385 2/20 0.35
CDK2 P24941 2/20 0.35
CDK7 P50613 2/20 0.35
CCNH P51946 2/20 0.35
CCNA1 P78396 2/20 0.35
CDK6 Q00534 2/20 0.35
TOP2A P11388 1/20 0.34
HTT P42858 1/20 0.34
PARG Q86W56 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4418543 0.82 KMT2A (0.43) CNR2HTR6POLBALDH1A1CYP1A2
SCHEMBL4429023 0.76 HTR6 (0.55) HTR6TOP2AHTT
SCHEMBL4422242 0.75 HTT (0.40) PKMCNR2HTR6POLBALDH1A1
SCHEMBL4419370 0.74 HTR6 (0.59) HTR6
SCHEMBL4422283 0.74 HTR6 (0.39) CNR2PTAFRHTR6POLBALDH1A1
SCHEMBL4426419 0.74 HTR6 (0.51) PKMHTR6POLBALDH1A1CYP1A2
SCHEMBL4277397 0.71 PKM (0.38) PKMHTR6
SCHEMBL4421797 0.70 HTR6 (0.54) HTR6
SCHEMBL4430912 0.70 KDM4E (0.38) CNR2HTR6POLBALDH1A1CYP1A2
SCHEMBL4416995 0.68 HTR6 (0.50) CNR2HTR6POLBALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1654258-A1 SULFONYLDIHYDRO- BENZIMIDAZOLONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS Wyeth (US) 2006-05-10 EP claimed
WO-2005009996-A1 SULFONYLDIHYDRO- BENZIMIDAZOLONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2005-02-03 WO claimed
US-20050020575-A1 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-01-27 US claimed
US-7544701-B2 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-06-09 US disclosed
EP-1654258-A1 SULFONYLDIHYDRO- BENZIMIDAZOLONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS Wyeth (US) 2006-05-10 EP disclosed
WO-2005009996-A1 SULFONYLDIHYDRO- BENZIMIDAZOLONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2005-02-03 WO disclosed
US-20050020575-A1 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020575-A1 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR1B PKM 1473/4885CNR2 36/4885PTAFR 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.